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Abstract
 
LIGHT (TNFSF14), a tumor necrosis factor superfamily member expressed by activated T
cells, binds to herpes virus entry mediator (HVEM) which is constitutively expressed by T cells
and costimulates T cell activation in a CD28-independent manner. Given interest in regulating
the effector functions of T cells in vivo, we examined the role of LIGHT-HVEM costimula-
tion in a murine cardiac allograft rejection model. Normal hearts lacked LIGHT or HVEM
mRNA expression, but allografts showed strong expression of both genes from day 3 after
transplant, and in situ hybridization and immunohistology-localized LIGHT and HVEM to in-
filtrating leukocytes. To test the importance of LIGHT expression on allograft survival, we
generated LIGHT
 
 
 
/
 
 
 
 mice by homologous recombination. The mean survival of fully major
histocompatibility complex–mismatched vascularized cardiac allografts in LIGHT
 
 
 
/
 
 
 
 mice (10
days, 
 
P 
 
 
 
 0.05) or cyclosporine A (CsA)-treated LIGHT
 
 
 
/
 
 
 
 mice (10 days, 
 
P
 
   
 
0.05) was only
slightly prolonged compared with LIGHT
 
 
 
/
 
 
 
 mice (7 days). However, mean allograft survival
in CsA-treated LIGHT
 
 
 
/
 
 
 
 allograft recipients (30 days) was considerably enhanced (
 
P 
 
 
 
0.001) compared with the 10 days of mean survival in either untreated LIGHT
 
 
 
/
 
 
 
 mice or
 
CsA-treated LIGHT
 
 
 
/
 
 
 
 controls. Molecular analyzes showed that the beneficial effects of target-
ing of LIGHT in CsA-treated recipients were accompanied by decreased intragraft expression of
 
interferon (IFN)-
 
 
 
, plus IFN-
 
 
 
–induced chemokine, inducible protein-10, and its receptor,
 
CXCR3. Treatment of LIGHT
 
 
 
/
 
 
 
 
 
allograft recipients with HVEM-Ig plus CsA also en-
hanced mean allograft survival (21 days) versus wild-type controls receiving HVEM-Ig (mean
 
of 7 days) or CsA alone (
 
P 
 
  
 
0.001). Our data suggest that T cell to T cell–mediated
LIGHT/HVEM-dependent costimulation is a significant component of the host response
leading to cardiac allograft rejection.
Key words: transplantation • allograft rejection • T cell activation • costimulation • TNF 
superfamily
 
Introduction
 
By binding to structurally related but distinct receptors,
TNF cytokine family members play key roles in inflam-
mation, immunity, and homeostasis (1). An extensive lit-
erature exists on how antigenic stimulation of T cells in
the absence of costimulation induces anergy, and addition
of a second or costimulatory signal such as ligation of
CD28 by B7–1 (CD80) or B7–2 (CD86) on dendritic
cells (DCs) promotes a primary T cell response. Various
CD28-independent costimulatory pathways are also now
recognized. In particular, accruing data suggest that TNF
superfamily members can function as costimulatory mole-
cules in T cell activation by delivering a second signal for
T cell proliferation, cytokine production, and Th1/Th2
differentiation (2).
LIGHT, whose name is derived from homologous to
lymphotoxins, exhibits inducible expression, and competes
with herpes simplex virus (HSV) glycoprotein D for her-
pesvirus entry mediator (HVEM/TR2), a receptor ex-
pressed by T lymphocytes (3), is a recently identified mem-
ber of the human (4) and mouse (5) TNF superfamily.
LIGHT is a 29-kD type II transmembrane protein pro-
duced by activated T cells (4), as well as monocytes and
granulocytes (6), and immature DCs (7). Apart from its re-
ceptor on T cells, HVEM, LIGHT binds to the lympho-
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toxin 
 
 
 
 receptor (LT
 
 
 
R) on stromal cells (4), and the
DcR3/TR6 soluble protein (8).
In vitro, LIGHT expression induces potent CD28-inde-
pendent costimulatory activity, leading to NF-
 
 
 
B activa-
tion, production of IFN-
 
 
 
 and other cytokines, and T cell
proliferation in response to allogeneic DCs (7, 9). In vivo
blockade studies show LIGHT is involved in promotion of
cytolytic T cell responses to tumors (5) and the develop-
ment of GVHD (5), and transgenic overexpression of
LIGHT within T cells leads to T cell expansion and causes
various severe autoimmune diseases (10–12). No data are
yet available concerning the role of the LIGHT/HVEM
pathway in solid organ transplantation. In this study, we
generated LIGHT deficient mice by gene targeting and
demonstrated that LIGHT is a regulator of host allogeneic
T cell activation and allograft rejection.
 
Materials and Methods
 
Generation of LIGHT
 
 
 
/
 
 
 
 Mice.
 
A targeting vector was con-
structed using a 10.5-kb genomic fragment containing exons 1–4
of the LIGHT gene. A 0.8-kb sequence around exon 1, including
ATG, was deleted and replaced by pMC1 neo, the targeting vec-
tor was linearized and electroporated into ES cells, and LIGHT
 
 
 
/
 
 
 
ES cell clones were selected in media containing G418 and Gan-
cyclovir, as described previously (13). The correctly targeted
event was screened by Southern blot analysis, and chimeric mice
were derived by blastocyst injection. Offspring of LIGHT
 
 
 
/
 
 
 
mice were crossed to produce LIGHT
 
 
 
/
 
 
 
 mice. Mice used in this
study were on a B6/129 background. Since human LIGHT maps
closely to the third complement protein (C3) (14), plasma C3
levels in LIGHT
 
 
 
/
 
 
 
 versus LIGHT
 
 
 
/
 
 
 
 were screened by radial
immunodiffusion using goat anti–mouse C3 antibody (Cappel,
ICN Pharmaceuticals).
 
Transplantation.
 
Male 6-wk-old BALB/c (H-2
 
d
 
), 129Sv/J
(H-2
 
b
 
), C57BL/6 (H-2
 
b
 
), and B6/129 (H-2
 
b
 
) mice were pur-
chased from The Jackson Laboratory and maintained in our spe-
cific pathogen-free facility. Heterotopic abdominal cardiac al-
lografting was done with the use of BALB/c donors and B6/129
recipients, as well as in some experiments, pure 129 or B6 recipi-
ents, using six allografts per experimental group (15); data re-
ported are from BALB
 
→
 
B6/129. Graft function was monitored
twice daily by palpation, and rejection confirmed by laparotomy
and histology. At harvest at rejection or at the time indicated,
midventricular samples were fixed in formalin for light micros-
copy or snap-frozen in liquid nitrogen and stored at –80
 
 
 
C for
immunohistology and RNA studies.
 
Posttransplant Therapies.
 
LIGHT
 
 
 
/
 
 
 
 or LIGHT
 
 
 
/
 
 
 
 allograft
recipients were treated with cyclosporin A (CsA) (Sigma-
Aldrich), dissolved in olive oil and administered daily (10 mg/kg
intraperitoneally) for 14 d after transplant. Additional LIGHT
 
 
 
/
 
 
 
recipients were treated with a mHVEM-human IgG1
(HVEM-Ig) fusion protein, which was generated using the ex-
tracellular region of HVEM (3), as described previously (4);
HVEM-Ig was purified by affinity chromatography and shown
by gel electrophoresis to be free of aggregation. Mice received
100 
 
 
 
g of HVEM-Ig daily, from the time of transplantation un-
til day 14, or control human IgG1 (Sigma-Aldrich); levels of en-
dotoxin contamination of these preparations were 
 
 
 
1 pg/ml as
shown using a Limulus amebocyte lysate assay (Associates of
Cape Cod).
 
RNA Isolation and RT-PCR Analysis of HVEM and LIGHT
Expression.
 
Total RNA was prepared from each recipient’s heart
and cardiac allograft using guanidine-thiocyanate, and RNA in-
tegrity was confirmed by electrophoresis (16). RNA was reverse
transcribed at 45
 
 
 
C for 60 min, 95
 
 
 
C for 3 min, and placed on ice.
For LIGHT detection, primers (mLIGHT1F, 5-ATGGAGAGT-
GTGGTACAGCCTTC-3; mLIGHT1R, 5-GACCATGA-
AAGCTCCGAAATAGG-3) were used. For HVEM, prim-
ers (mHVEM1F, 5-ATGGAACCTCTCCCAGGATGGG-3;
mHVEM1R, 5-TCAGTTGGAGGCTGTCTCCTCC-3) were
used. Each three-step thermal cycle for routine PCR analysis in-
cluded 30 s at 95
 
 
 
C, 30 s at 60
 
 
 
C, and 60 s at 72
 
 
 
C; additional
PCR reactions were performed for 35 cycles. PCR products were
visualized by ethidium bromide staining of agarose gels and iden-
tified by size markers. A negative control containing all reagents
except cDNA was included in each PCR analysis.
 
In Situ Hybridization (ISH).
 
LIGHT riboprobes were synthe-
sized from T3 (sense probe) and T7 (antisense probe) promoters,
labeled with biotin-UTP (Roche Laboratories) and used to local-
ize LIGHT mRNA expression within cardiac tissue sections by
ISH as described previously (17).
 
RNase Protection Assays.
 
RNA was evaluated by the Ribo-
quant system (BD PharMingen), using mouse template sets mCK-1
and mCK-3b for cytokines, mCK5 for chemokines, and mCR5
and mCR6 for CC and CXC chemokine receptors, respectively.
A riboprobe for mouse CXCR3 was prepared in house (18).
Methods for in vitro transcription, riboprobe purification and use,
plus densitometric analysis and normalization of data to L32 and
GAPDH gene expression, were as described previously (17).
 
Immunopathology.
 
Hearts were fixed in formalin, paraffin-
embedded, and stained with hematoxylin and eosin. Cryostat sec-
tions fixed in paraformaldehyde-lysine-periodate were stained by
immunoperoxidase using mAbs to mouse leukocytes (BD
PharMingen), anti-LIGHT antibody (Santa Cruz Biotechnol-
ogy), or isotype-matched controls (15).
 
Results and Discussion
 
Given the importance of LIGHT expression in the de-
velopment of T cell activation in vivo, including in host T
cell–dependent antitumor responses (5, 6), we undertook a
serial study of LIGHT and HVEM expression during the
development of cardiac allograft rejection across a full
MHC disparity. Total RNA was prepared from each recip-
ient’s heterotopic transplant and own native heart after col-
lection on days 3 and 7 after transplant, and HVEM and
LIGHT mRNA expression were analyzed by RT-PCR.
Negligible LIGHT or HVEM mRNA was detected in na-
tive hearts, but both LIGHT and HVEM were markedly
upregulated at days 3 and 7 after transplant (Fig. 1 a).
LIGHT mRNA expression was localized by ISH to cells
with the morphology of small mononuclear cells (Fig. 1 b),
and similar localization of HVEM mRNA, plus focal endo-
thelial expression, was detected by ISH for HVEM (data
not shown). Immunoperoxidase studies confirmed expres-
sion of LIGHT protein by infiltrating leukocytes (Fig. 1 c);
labeled cells included lymphocytes, plus some inflammatory
macrophages and tissue DCs.
To determine the role of LIGHT expression in allograft
rejection, we used homologous recombination to disrupt
exon 1, containing the ATG initiation codon, of the LIGHT 
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gene (Fig. 2). Mice heterologous and homozygous for the
LIGHT mutation were normal in appearance, growth and
fertility, had normal numbers of T and B cells, monocytes
and granulocytes, and normal lymphoid architecture.
LIGHT
 
 
 
/
 
 
 
 mice also had normal levels of plasma C3 despite
the chromosomal proximity of LIGHT and C3 genes (14);
detailed characterization of these mice is underway.
Homozygous LIGHT
 
 
 
/
 
 
 
 mice were used as recipients of
fully MHC-disparate cardiac allografts. Whereas LIGHT
 
 
 
/
 
 
 
mice rejected BALB/c cardiac allografts within 1 wk,
LIGHT
 
 
 
/
 
 
 
 mice maintained their grafts for an extra 3–4 d
(Fig. 3 a), which was about as effective as CsA (10 mg/kg/d)
in mice (both 
 
P 
 
  
 
0.05 vs. untreated LIGHT
 
 
 
/
 
 
 
 
 
recipients).
 
However, use of the same regimen of CsA in LIGHT
 
 
 
/
 
 
 
mice led to significantly prolonged engraftment (
 
 
 
30 d, 
 
P 
 
 
 
0.001) (Fig. 3 a), indicating a synergistic effect of CsA and
LIGHT targeting on allograft survival. Histologic analysis
showed that rejecting grafts harvested at 7 d from LIGHT
 
 
 
/
 
 
 
mice, or LIGHT
 
 
 
/
 
 
 
 recipients treated with CsA, were mor-
phologically similar to allografts harvested form control
untreated LIGHT
 
 
 
/
 
 
 
 recipients (Fig. 3 b), with diffuse
mononuclear cell infiltrates and focal myocyte necrosis. In
contrast, allografts harvested at day 7 from LIGHT
 
 
 
/
 
 
 
 recip-
ients treated with CsA showed a marked absence of leuko-
cyte infiltration and essentially normal morphology.
Given concerns that gene-targeted mice may not always
reveal the role of a given gene in the normal state because
of secondary effects or compensatory responses, we investi-
gated whether targeting of LIGHT was also beneficial in
wild-type allograft recipients. We constructed an HVEM–
Ig fusion protein for therapeutic blockade of the effects of
endogenous LIGHT on host HVEM
 
 
 
 T cells. In line with
the modest effects of LIGHT targeting by homologous re-
combination in this strong MHC disparity, we found nei-
ther HVEM-Ig nor control IgG1 had any significant effect
on allograft survival in LIGHT
 
 
 
/
 
 
 
 recipients (
 
P 
 
  
 
0.05),
whereas HVEM-Ig, but not control IgG1, was markedly
synergistic with a subtherapeutic dose of CsA in prolonging
graft survival (
 
P 
 
  
 
0.001) (Fig. 3 c).
Expression of cytokines, chemokines, and their receptors
by host leukocytes vary during graft rejection. We used
RNase protection assays to examine the likely mechanisms
Figure 1. Analysis of LIGHT and HVEM expression during allograft
rejection. (a) Northern analysis of LIGHT and HVEM in serial cardiac
transplants (T) rejected by day 7 versus each recipient’s native heart (N).
(b) ISH analysis of graft LIGHT mRNA expression at day 7 posttrans-
plant is restricted to focal mononuclear cells (sense control, left). (c) Im-
munoperoxidase staining shows LIGHT protein expression by infiltrating
mononuclear leukocytes at day 7 posttransplant, including in cell clumps
containing larger, branching DC-like cells (arrows) (IgG control, right).
Scale bars, 100  . Data in each case are representative of the results from
three samples per group per time point.
Figure 2. Generation of LIGHT /  mice. (a) Genomic organization of
the murine LIGHT locus and resulting mutation induced by the targeting
event; exons are filled boxes. A LIGHT gene-targeting construct was
generated to replace exon 1 of LIGHT containing the initiating me-
thionine (ATG) with the neomycin resistance gene (NEO). (b) Southern
analysis of LIGHT wild-type ( / ), heterozygous knockout ( / ), and
homozygous knockout ( / ) mouse genomic DNA. Homologous re-
combination with the knockout construct results in the introduction of
an Xba (X) site when using a flanking probe. (c) Northern analysis of
LIGHT wild-type ( / ) and homozygous knockout ( / ) mouse liver
RNA using a probe containing the entire coding region of LIGHT; blots
were reprobed with a GAPDH probe to evaluate RNA loading. 
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Figure 3. Effects of targeting LIGHT on the survival of fully MHC-mismatched
cardiac allografts (H-2d→H2b). (a) Compared with untreated LIGHT /  recipients,
LIGHT /  recipients, or LIGHT /  recipients treated with a subtherapeutic course
of CsA, maintained their cardiac grafts for an extra 2–3 d (*P   0.05), whereas use of
the same sub-therapeutic CsA regimen in LIGHT /  recipients synergistically pro-
longed graft survival as compared with each of the other groups (**P   0.001). (b)
Histologic analysis of allografts harvested at day 7 showed similar mononuclear cell
infiltration and myocardial injury in LIGHT / , LIGHT / , and LIGHT /  recipi-
ents treated with CsA (day 10). By contrast, use of CsA in LIGHT /  mice sup-
pressed leukocyte recruitment and graft injury (hematoxylin and eosin, original mag-
nifications:   100). (c) Beneficial effects of targeting LIGHT were also seen in
LIGHT /  recipients since, in contrast to the effects of control IgG1 or HVEM-Ig
(P   0.05), or IgG/CsA alone (*P   0.05), HVEM-Ig plus low-dose CsA significantly
prolonged cardiac allograft survival (**P   0.001 versus each of the other groups).
Figure 4. Mechanisms underly-
ing beneficial effects of targeting
LIGHT in allograft recipients. (a)
RNase protection assay comparison
of intragraft Th1- and Th2-associ-
ated cytokines in control normal
heart versus allografts harvested at
day 7 after transplant. Use of CsA
had minimal effects on cytokine
expression in LIGHT /  mice,
whereas marked suppression of IL-2,
IL-10, and IFN-  were seen in
LIGHT /  mice treated with CsA
versus untreated LIGHT /  recipi-
ents. (b) RNase protection assay of
the same samples as in panel a, shows
suppression of LT- , TNF- , and
IFN-  expression with use of CsA in
LIGHT /  recipients, and modestly
enhanced expression of TGF- 2. Data
are representative of three allografts
per group per time-point. 
799
 
Ye et al. Brief Definitive Report
 
by which targeting of LIGHT, especially with concomitant
CsA, induced prolonged graft survival. Use of CsA in
LIGHT
 
 
 
/
 
 
 
 mice suppressed the intragraft upregulation of
multiple cytokine mRNAs, including IFN-
 
 
 
, IL-2, and IL-
10 (Fig. 4 a), plus LT-
 
 
 
 and TNF-
 
 
 
 (Fig. 4 b). Consistent
with these effects and the reduction in cellularity apparent
histologically, expression of several IFN-
 
 
 
-induced chemo-
kines, including RANTES, MIP-1
 
 
 
, MIP-1
 
 
 
, and IP-10
was down-regulated in LIGHT
 
 
 
/
 
 
 
 mice treated with CsA
(Fig. 5 a). Along with the decreased chemokine expression,
LIGHT
 
 
 
/
 
 
 
 
 
mice treated with CsA had modest reductions
in CC-chemokine receptor expression (Fig. 5 b) and mark-
edly decreased expression of the chemokine receptor for
IP-10, CXCR3 (Fig. 5 c), which is expressed by Th1 and
Tc1 lymphocytes (13).
Our prior studies in this model showed that donor-
derived IP-10 production (19) and concomitant infiltration
by CXCR3
 
 
 
 leukocytes (13) play central roles in the de-
velopment of allograft rejection, such that targeting of ei-
ther IP-10 production or CXCR3 expression markedly
prolongs allograft survival. We also recently reported that
the IP-10/CXCR3 pathway is active during development
of human cardiac allograft rejection (20). IP-10 production
is regulated by NF-
 
 
 
B (21), and LIGHT-induced costimu-
lation causes NF-
 
 
 
B activation and translocation in T cells
(9), leading to production of IFN-
 
 
 
 (7). It is likely that
modulation of this pathway by inhibition of LIGHT co-
stimulation is at least one important mechanism of action in
our model, and one which is potentiated by the effects of a
subtherapeutic regimen of CsA, which can also diminish
NF-
 
 
 
B activation and IFN-
 
 
 
 production (22). Neverthe-
less, given recent evidence of several distinct molecular
forms of LIGHT, which are directed to distinct cellular
compartments, including the extracellular space, the mem-
brane, and the cytosol (14), and findings that LIGHT over-
expression by T cells promotes inflammation via activation
of multiple pathways (10–12), there remain many addi-
tional potential mechanisms by which targeting of LIGHT
in conjunction with CsA could be beneficial.
Our studies show a modest role for LIGHT costimula-
tion by itself in promoting allograft rejection, but in con-
trast to some other combinations of therapeutic agents and
costimulation blockade, such as the use of CD154 mAb
plus CsA (23), the effects of targeting LIGHT-HVEM in-
teractions are markedly synergistic with CsA. Their com-
bined use prevents acute allograft rejection, modulates in-
tragraft cytokine and chemokine production, and decreases
the infiltration of host immunocompetent cells. These data
suggest exploration of the role of LIGHT costimulation in
less rigorous models as well as in combination with other
therapeutic approaches. We conclude that the LIGHT-
 
Figure 5.
 
Targeting of LIGHT is synergistic with CsA in effects at day 7
after transplant on intragraft expression of (a) the chemokines lymphotactin
(LTN), RANTES, MIP-1
 
 
 
, MIP-1
 
 
 
, MCP-1, IP-10, and TCA-3; (b)
the CC chemokine receptors CCR1, CCR2, and CCR5; and especially
(c) the key allograft rejection-linked CXC chemokine receptor, CXCR3.
Data are representative of three allografts per group per time-point. 
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HVEM pathway is yet another of the rapidly expanding
number of costimulation pathways which require attention
in efforts to promote the development of safer, less toxic
therapeutic protocols which may eventually facilitate de-
velopment of clinical allograft tolerance.
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